Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Signal Genetics Agrees to Buy ChipDX to Gain Cancer Diagnostics

Feb. 2 (Bloomberg) -- Signal Genetics, a closely held cancer testing company, agreed to buy ChipDX LLC to add diagnostic products in development for lung, breast and colon cancers.

The acquisition also adds closely held ChipDX’s technology to enable for remote interpretation of tests, New York-based Signal said today. Financial details weren’t disclosed.

Signal makes a prognostic test for multiple myeloma called MyPRS Plus, and will use its sales team to bring ChipDX’s products to market, the company said. ChipDX’s BreastGeneDX, ColonGeneDX and LungGeneDX products are designed to determine patients’ cancer risk levels.

“The acquisition of the intellectual property and patents of ChipDX dramatically expands and enhances our oncology pipeline,” Signal Chief Executive Officer Joe Hernandez said in a statement. “The addition of ChipDX’s bioinformatics capabilities drastically reduces our time to market with novel molecular tests designed to facilitate better patient outcomes at a lower cost profile.”

To contact the reporter on this story: Meg Tirrell in New York at

To contact the editor responsible for this story: Reg Gale at

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.